Cdiffense

Sanofi vaccines division Sanofi Pasteur initiated Cdiffense Phase III Study of investigational vaccine for prevention of primary symptomatic Clostridium difficile infection (CDI)

Cdiffense trial to evaluate vaccine against a leading cause of life-threatening, healthcare-associated infections worldwide Lyon, France, 06-8-2013 — /EuropaWire/ — Sanofi Pasteur,…

11 years ago